n(g),n(g')-dimethyl-l-arginine has been researched along with Heart Failure in 41 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Elevated plasma levels of asymmetric dimethylarginine (ADMA), an endothelial nitric oxide synthase (eNOS) inhibitor, may contribute to endothelial dysfunction in chronic heart failure (CHF)." | 9.13 | Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with non-ischaemic heart failure. ( Florkowski, CM; Frampton, CM; George, PM; Scott, RS; Sies, CW; Strey, CH; Young, JM, 2008) |
| " The arginine : ADMA ratio in particular is of clinical importance and the restoration of this ratio is expedient to restore several functions that are disturbed during critical illness." | 8.90 | Asymmetric dimethylarginine and critical illness. ( Brinkmann, SJ; Buijs, N; de Boer, MC; van Leeuwen, PA, 2014) |
| " The dimethylarginines asymmetric (ADMA) and symmetric dimethylarginine (SDMA) can impair the synthesis of NO and are elevated in patients with cardiovascular disease, including heart failure (HF)." | 7.85 | Higher serum asymmetric dimethylarginine is related to higher risk of heart failure in the EPIC-Potsdam study. ( Atzler, D; Boeing, H; Böger, RH; Cordts, K; di Giuseppe, R; Menzel, J; Schwedhelm, E; Weikert, C; Wirth, J, 2017) |
| "The effects of eicosapentaenoic acid (EPA) on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure (CHF) patients with dyslipidemia remain unclear." | 7.80 | Effects of eicosapentaenoic acid on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure patients with dyslipidemia. ( Atarashi, H; Kohashi, K; Kosugi, M; Kusama, Y; Morisawa, T; Nakagomi, A; Saiki, Y; Shimizu, W, 2014) |
| "The present study was designed to investigate whether oxymatrine could attenuate isoproterenol-induced heart failure via regulation of asymmetric dimethylarginine (ADMA) metabolism in rats." | 7.80 | Cardioprotective effects of oxymatrine on isoproterenol-induced heart failure via regulation of DDAH/ADMA metabolism pathway in rats. ( Dai, G; Liu, J; Liu, YK; Wang, X; Wang, Y; Xu, Q; Xu, X; Zhang, J; Zhang, W, 2014) |
| "To investigate the prognostic value of circulating levels of asymmetric dimethylarginine (ADMA) in patients with acute decompensation of (New York Heart Association (NYHA) class III/IV) chronic heart failure and reduced left ventricular ejection fraction." | 7.78 | Plasma asymmetric dimethylarginine and mortality in patients with acute decompensation of chronic heart failure. ( Argyrakis, KS; Batika, PC; Foussas, SG; Makrygiannis, SS; Melidonis, A; Patsourakos, NG; Prekates, AA; Theodossis Georgilas, A; Tsiaousis, GZ; Tzerefos, SP; Velissaris, D; Zairis, MN, 2012) |
| "The aim of this study was to relate levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthase, L-arginine, the substrate for NO generation, and radical oxygen species (ROS) formation to severity of chronic heart failure." | 7.77 | The L-arginine-asymmetric dimethylarginine ratio is strongly related to the severity of chronic heart failure. No effects of exercise training. ( Arnesen, H; Bratseth, V; Nilsson, BB; Seljeflot, I; Westheim, AS, 2011) |
| "This prospective study investigated whether plasma asymmetric dimethylarginine (ADMA) concentrations are related to cardiovascular events in patients with acute heart failure." | 7.74 | Plasma asymmetric dimethylarginine and cardiovascular events in patients with acute decompensated heart failure. ( Altenberger, J; Dückelmann, C; Haider, DG; Mittermayer, F; Wolzt, M, 2008) |
| "Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is elevated in congestive heart failure (CHF) concomitantly with the higher levels of nitric oxide (NO) and cytokines." | 7.72 | High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level. ( Hanada, H; Ishizaka, H; Kamada, T; Matsunaga, T; Okumura, K; Osanai, T; Saitoh, M, 2003) |
| "Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthases that limits nitric oxide bioavailability and can increase production of NOS derived reactive oxidative species." | 6.53 | Effect of asymmetric dimethylarginine (ADMA) on heart failure development. ( Chen, A; Chen, Y; Fassett, JT; Hou, L; Liu, X; Xu, D; Xu, Y; Yang, L; Zhuang, Y, 2016) |
| "Because depression is associated with poor HF outcomes, the present study tested the hypothesis that depression is associated with a dysregulated NO pathway in patients with HF." | 5.42 | Nitric oxide dysregulation in patients with heart failure: the association of depressive symptoms with L-arginine, asymmetric dimethylarginine, symmetric dimethylarginine, and isoprostane. ( Eisel, UL; Garrelds, IM; Kop, WJ; Mommersteeg, PM; Schalkwijk, CG; Schoemaker, RG, 2015) |
| " We evaluated relation in HF patients among cytokines and asymmetric dimethylarginine (ADMA) and left ventricular ejection fraction (LVEF) at baseline and after long-term administration of carvedilol." | 5.35 | Differential long-term effects of carvedilol on proinflammatory and antiinflammatory cytokines, asymmetric dimethylarginine, and left ventricular function in patients with heart failure. ( Alfieri, AB; Arioli, F; Bassanelli, G; Briceno, L; Cuko, A; Fragasso, G; Margonato, A; Montano, C; Palloshi, A; Ruotolo, G; Spoladore, R, 2008) |
| "Elevated levels of arginine derivatives in the NO pathway, such as asymmetric dimethylarginine (ADMA), are related to disease severity and reduced exercise capacity in heart failure (HF)." | 5.27 | Relationship between exercise intervention and NO pathway in patients with heart failure with preserved ejection fraction. ( Atzler, D; Baldassarri, F; Böger, RH; Cordts, K; Düngen, HD; Duvinage, A; Edelmann, F; Halle, M; Haller, B; Hasenfuss, G; Müller, S; Pieske, B; Pressler, A; Schwedhelm, E; Suchy, C; Wachter, R, 2018) |
| "Elevated plasma levels of asymmetric dimethylarginine (ADMA), an endothelial nitric oxide synthase (eNOS) inhibitor, may contribute to endothelial dysfunction in chronic heart failure (CHF)." | 5.13 | Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with non-ischaemic heart failure. ( Florkowski, CM; Frampton, CM; George, PM; Scott, RS; Sies, CW; Strey, CH; Young, JM, 2008) |
| "Chronic heart failure is associated with increased levels of hypoxanthine and decreased levels of nitrite." | 5.11 | Home-based exercise training modulates pro-oxidant substrates in patients with chronic heart failure. ( Böger, R; Clark, AL; Coats, AJ; Niebauer, J; Webb-Peploe, KM, 2005) |
| "Nutritional factors such as magnesium, folic acid, vitamins B12 and B6, L-arginine, and polyunsaturated fatty acids (PUFAs) appear to be significantly beneficial for patients with coronary artery disease (CAD), and in the prevention and arresting the progression of HF and cardiac arrhythmias." | 4.91 | Nutritional factors in the prevention and management of coronary artery disease and heart failure. ( Das, UN, 2015) |
| " The arginine : ADMA ratio in particular is of clinical importance and the restoration of this ratio is expedient to restore several functions that are disturbed during critical illness." | 4.90 | Asymmetric dimethylarginine and critical illness. ( Brinkmann, SJ; Buijs, N; de Boer, MC; van Leeuwen, PA, 2014) |
| " The dimethylarginines asymmetric (ADMA) and symmetric dimethylarginine (SDMA) can impair the synthesis of NO and are elevated in patients with cardiovascular disease, including heart failure (HF)." | 3.85 | Higher serum asymmetric dimethylarginine is related to higher risk of heart failure in the EPIC-Potsdam study. ( Atzler, D; Boeing, H; Böger, RH; Cordts, K; di Giuseppe, R; Menzel, J; Schwedhelm, E; Weikert, C; Wirth, J, 2017) |
| "The effects of eicosapentaenoic acid (EPA) on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure (CHF) patients with dyslipidemia remain unclear." | 3.80 | Effects of eicosapentaenoic acid on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure patients with dyslipidemia. ( Atarashi, H; Kohashi, K; Kosugi, M; Kusama, Y; Morisawa, T; Nakagomi, A; Saiki, Y; Shimizu, W, 2014) |
| "The present study was designed to investigate whether oxymatrine could attenuate isoproterenol-induced heart failure via regulation of asymmetric dimethylarginine (ADMA) metabolism in rats." | 3.80 | Cardioprotective effects of oxymatrine on isoproterenol-induced heart failure via regulation of DDAH/ADMA metabolism pathway in rats. ( Dai, G; Liu, J; Liu, YK; Wang, X; Wang, Y; Xu, Q; Xu, X; Zhang, J; Zhang, W, 2014) |
| "To investigate the prognostic value of circulating levels of asymmetric dimethylarginine (ADMA) in patients with acute decompensation of (New York Heart Association (NYHA) class III/IV) chronic heart failure and reduced left ventricular ejection fraction." | 3.78 | Plasma asymmetric dimethylarginine and mortality in patients with acute decompensation of chronic heart failure. ( Argyrakis, KS; Batika, PC; Foussas, SG; Makrygiannis, SS; Melidonis, A; Patsourakos, NG; Prekates, AA; Theodossis Georgilas, A; Tsiaousis, GZ; Tzerefos, SP; Velissaris, D; Zairis, MN, 2012) |
| "The aim of this study was to relate levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthase, L-arginine, the substrate for NO generation, and radical oxygen species (ROS) formation to severity of chronic heart failure." | 3.77 | The L-arginine-asymmetric dimethylarginine ratio is strongly related to the severity of chronic heart failure. No effects of exercise training. ( Arnesen, H; Bratseth, V; Nilsson, BB; Seljeflot, I; Westheim, AS, 2011) |
| "Systemic inflammation and elevated circulating levels of the endogenous nitric oxide inhibitor asymmetrical dimethylarginine (ADMA) have been associated with increased risk in cardiogenic shock (CS)." | 3.77 | Inflammation and reduced endothelial function in the course of severe acute heart failure. ( Hermansen, SE; How, OJ; Kalstad, T; Myrmel, T, 2011) |
| "Elevated blood concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric-oxide (NO) synthase, are found in association with diabetes, hypertension, congestive heart failure, and atherosclerosis." | 3.76 | Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production. ( Lentz, SR; Murry, DJ; Rodionov, RN; Stevens, JW; Vaulman, SF, 2010) |
| "This prospective study investigated whether plasma asymmetric dimethylarginine (ADMA) concentrations are related to cardiovascular events in patients with acute heart failure." | 3.74 | Plasma asymmetric dimethylarginine and cardiovascular events in patients with acute decompensated heart failure. ( Altenberger, J; Dückelmann, C; Haider, DG; Mittermayer, F; Wolzt, M, 2008) |
| "In a cohort of 246 dialysis patients without heart failure at baseline we tested the combined prognostic power of three well-established biomarkers: brain natriuretic peptide (BNP), C-reactive protein (CRP), and asymmetric dimethyl arginine (ADMA)." | 3.73 | Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. ( Cutrupi, S; Malatino, LS; Mallamaci, F; Tripepi, G; Zoccali, C, 2005) |
| "We assessed blood concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) as well as renal haemodynamics to compare normotensive patients with mild heart failure (n = 12, seven males, 70 +/- 1 years, 72." | 3.72 | Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure. ( Bode-Böger, SM; Fliser, D; Graf, S; Haller, H; Kielstein, JT; Klein, G, 2003) |
| "Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is elevated in congestive heart failure (CHF) concomitantly with the higher levels of nitric oxide (NO) and cytokines." | 3.72 | High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level. ( Hanada, H; Ishizaka, H; Kamada, T; Matsunaga, T; Okumura, K; Osanai, T; Saitoh, M, 2003) |
| "Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthases that limits nitric oxide bioavailability and can increase production of NOS derived reactive oxidative species." | 2.53 | Effect of asymmetric dimethylarginine (ADMA) on heart failure development. ( Chen, A; Chen, Y; Fassett, JT; Hou, L; Liu, X; Xu, D; Xu, Y; Yang, L; Zhuang, Y, 2016) |
| "This case-cohort study included Chronic Renal Insufficiency Cohort participants with baseline diabetes, estimated glomerular filtration rate <60 mL/min/1." | 1.91 | Association of urine and plasma ADMA with atherosclerotic risk in DKD cardiovascular disease risk in diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. ( Anderson, AH; Bhat, Z; Brown, J; Brunengraber, H; Charleston, J; Chen, J; Feldman, HI; He, J; Hostetter, TH; Hsu, CY; Ix, JH; Kimmel, PL; Mehta, R; Rao, P; Sapa, H; Schelling, JR; Schrauben, SJ; Seegmiller, JC; Shafi, T; Shlipak, MG; Townsend, R; Vasan, RS; Xie, D; Zhang, X, 2023) |
| "Because depression is associated with poor HF outcomes, the present study tested the hypothesis that depression is associated with a dysregulated NO pathway in patients with HF." | 1.42 | Nitric oxide dysregulation in patients with heart failure: the association of depressive symptoms with L-arginine, asymmetric dimethylarginine, symmetric dimethylarginine, and isoprostane. ( Eisel, UL; Garrelds, IM; Kop, WJ; Mommersteeg, PM; Schalkwijk, CG; Schoemaker, RG, 2015) |
| "Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) which plays an important role in controlling vascular tone and regulates the contractile properties of cardiac myocytes." | 1.37 | The biological effect of pharmacological treatment on dimethylaminohydrolases (DDAH-1) and cationic amino acid transporter-1 (CAT-1) expression in patients with acute congestive heart failure. ( Bucciarelli, T; D'Orazio, N; Felaco, M; Franceschelli, S; Gaeta, R; Grilli, A; Riccioni, G; Speranza, L, 2011) |
| " Increased ADMA in cell culture supernatant (SN) from pre-miR-199a-CM or siRNA-Ube2i/2g1-CM lowered nitric oxide (NO) bioavailability of rat cardiac endothelial cells while lowering ADMA concentration in CM SNs by the PRMT inhibitor arginine methyltransferase inhibitor 1 (AMI-1) (100 µM) improved NO bioavailability." | 1.37 | Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart: a key role for ubiquitin-conjugating enzymes. ( Brundiers, S; Castoldi, M; Drexler, H; Eder, M; Haghikia, A; Hilfiker-Kleiner, D; Missol-Kolka, E; Muckenthaler, MU; Petrasch-Parwez, E; Scherr, M; Stapel, B; Thum, T; Tsikas, D; Venturini, L, 2011) |
| " We evaluated relation in HF patients among cytokines and asymmetric dimethylarginine (ADMA) and left ventricular ejection fraction (LVEF) at baseline and after long-term administration of carvedilol." | 1.35 | Differential long-term effects of carvedilol on proinflammatory and antiinflammatory cytokines, asymmetric dimethylarginine, and left ventricular function in patients with heart failure. ( Alfieri, AB; Arioli, F; Bassanelli, G; Briceno, L; Cuko, A; Fragasso, G; Margonato, A; Montano, C; Palloshi, A; Ruotolo, G; Spoladore, R, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.88) | 18.2507 |
| 2000's | 11 (26.83) | 29.6817 |
| 2010's | 25 (60.98) | 24.3611 |
| 2020's | 3 (7.32) | 2.80 |
| Authors | Studies |
|---|---|
| Pourrajab, B | 1 |
| Naderi, N | 1 |
| Janani, L | 1 |
| Hajahmadi, M | 1 |
| Mofid, V | 1 |
| Dehnad, A | 1 |
| Sohouli, MH | 1 |
| Hosseini, S | 1 |
| Shidfar, F | 1 |
| Schrauben, SJ | 1 |
| Sapa, H | 1 |
| Xie, D | 1 |
| Zhang, X | 1 |
| Anderson, AH | 1 |
| Shlipak, MG | 1 |
| Hsu, CY | 1 |
| Shafi, T | 1 |
| Mehta, R | 1 |
| Bhat, Z | 1 |
| Brown, J | 1 |
| Charleston, J | 1 |
| Chen, J | 1 |
| He, J | 1 |
| Ix, JH | 1 |
| Rao, P | 1 |
| Townsend, R | 1 |
| Kimmel, PL | 1 |
| Vasan, RS | 1 |
| Feldman, HI | 1 |
| Seegmiller, JC | 1 |
| Brunengraber, H | 1 |
| Hostetter, TH | 1 |
| Schelling, JR | 1 |
| Pan, W | 1 |
| Lian, B | 1 |
| Lu, H | 1 |
| Liao, P | 1 |
| Guo, L | 1 |
| Zhang, M | 1 |
| Potočnjak, I | 1 |
| Radulović, B | 1 |
| Degoricija, V | 1 |
| Trbušić, M | 1 |
| Pregartner, G | 1 |
| Berghold, A | 1 |
| Meinitzer, A | 1 |
| Frank, S | 1 |
| Baldassarri, F | 1 |
| Schwedhelm, E | 2 |
| Atzler, D | 2 |
| Böger, RH | 2 |
| Cordts, K | 2 |
| Haller, B | 1 |
| Pressler, A | 1 |
| Müller, S | 1 |
| Suchy, C | 1 |
| Wachter, R | 1 |
| Düngen, HD | 1 |
| Hasenfuss, G | 1 |
| Pieske, B | 1 |
| Halle, M | 1 |
| Edelmann, F | 1 |
| Duvinage, A | 1 |
| Lundgren, J | 1 |
| Sandqvist, A | 1 |
| Hedeland, M | 1 |
| Bondesson, U | 1 |
| Wikström, G | 1 |
| Rådegran, G | 1 |
| Liu, X | 2 |
| Xu, X | 2 |
| Shang, R | 1 |
| Chen, Y | 2 |
| Brinkmann, SJ | 1 |
| de Boer, MC | 1 |
| Buijs, N | 1 |
| van Leeuwen, PA | 1 |
| Kohashi, K | 1 |
| Nakagomi, A | 1 |
| Saiki, Y | 1 |
| Morisawa, T | 1 |
| Kosugi, M | 1 |
| Kusama, Y | 1 |
| Atarashi, H | 1 |
| Shimizu, W | 1 |
| Zhang, W | 1 |
| Zhang, J | 1 |
| Liu, YK | 1 |
| Liu, J | 1 |
| Wang, X | 2 |
| Xu, Q | 1 |
| Wang, Y | 1 |
| Dai, G | 1 |
| Das, UN | 1 |
| Mommersteeg, PM | 1 |
| Schoemaker, RG | 1 |
| Eisel, UL | 1 |
| Garrelds, IM | 1 |
| Schalkwijk, CG | 1 |
| Kop, WJ | 1 |
| Sandri, M | 1 |
| Viehmann, M | 1 |
| Adams, V | 1 |
| Rabald, K | 1 |
| Mangner, N | 1 |
| Höllriegel, R | 1 |
| Lurz, P | 1 |
| Erbs, S | 1 |
| Linke, A | 1 |
| Kirsch, K | 1 |
| Möbius-Winkler, S | 1 |
| Thiery, J | 1 |
| Teupser, D | 1 |
| Hambrecht, R | 1 |
| Schuler, G | 1 |
| Gielen, S | 1 |
| Hou, L | 1 |
| Xu, D | 1 |
| Chen, A | 1 |
| Yang, L | 1 |
| Zhuang, Y | 1 |
| Xu, Y | 1 |
| Fassett, JT | 1 |
| Wirth, J | 1 |
| di Giuseppe, R | 1 |
| Menzel, J | 1 |
| Boeing, H | 1 |
| Weikert, C | 1 |
| Dückelmann, C | 2 |
| Mittermayer, F | 2 |
| Haider, DG | 2 |
| Altenberger, J | 2 |
| Wolzt, M | 2 |
| Alfieri, AB | 1 |
| Briceno, L | 1 |
| Fragasso, G | 1 |
| Spoladore, R | 1 |
| Palloshi, A | 1 |
| Bassanelli, G | 1 |
| Montano, C | 1 |
| Arioli, F | 1 |
| Cuko, A | 1 |
| Ruotolo, G | 1 |
| Margonato, A | 1 |
| Yilmaz, MB | 1 |
| Yontar, OC | 1 |
| Paul, B | 1 |
| Whiting, MJ | 1 |
| De Pasquale, CG | 1 |
| Mangoni, AA | 1 |
| Rodionov, RN | 1 |
| Murry, DJ | 1 |
| Vaulman, SF | 1 |
| Stevens, JW | 1 |
| Lentz, SR | 1 |
| Haghikia, A | 2 |
| Missol-Kolka, E | 1 |
| Tsikas, D | 1 |
| Venturini, L | 1 |
| Brundiers, S | 1 |
| Castoldi, M | 1 |
| Muckenthaler, MU | 1 |
| Eder, M | 1 |
| Stapel, B | 1 |
| Thum, T | 1 |
| Petrasch-Parwez, E | 1 |
| Drexler, H | 1 |
| Hilfiker-Kleiner, D | 1 |
| Scherr, M | 1 |
| Seljeflot, I | 2 |
| Nilsson, BB | 1 |
| Westheim, AS | 1 |
| Bratseth, V | 1 |
| Arnesen, H | 1 |
| Hermansen, SE | 1 |
| Kalstad, T | 1 |
| How, OJ | 1 |
| Myrmel, T | 1 |
| Tsarouhas, K | 1 |
| Karatzaferi, C | 1 |
| Tsitsimpikou, C | 1 |
| Haliassos, A | 1 |
| Kouretas, D | 1 |
| Pavlidis, P | 1 |
| Veskoukis, A | 1 |
| Adamopoulos, S | 1 |
| Kyriakides, Z | 1 |
| Constantinou, L | 1 |
| Koutedakis, Y | 1 |
| Rentoukas, E | 1 |
| Riccioni, G | 3 |
| Speranza, L | 3 |
| Scotti, L | 1 |
| Bucciarelli, V | 1 |
| Di Ilio, E | 1 |
| D'Orazio, N | 2 |
| Pesce, M | 2 |
| Aceto, A | 1 |
| Sorrenti, V | 1 |
| Frigiola, A | 1 |
| Bucciarelli, T | 3 |
| Franceschelli, S | 2 |
| Gaeta, R | 1 |
| Felaco, M | 2 |
| Grilli, A | 1 |
| Scherbakov, N | 1 |
| Sandek, A | 1 |
| Martens-Lobenhoffer, J | 1 |
| Kung, T | 1 |
| Turhan, G | 1 |
| Liman, T | 1 |
| Ebinger, M | 1 |
| von Haehling, S | 1 |
| Bode-Böger, SM | 2 |
| Endres, M | 1 |
| Doehner, W | 1 |
| Zairis, MN | 1 |
| Patsourakos, NG | 1 |
| Tsiaousis, GZ | 1 |
| Theodossis Georgilas, A | 1 |
| Melidonis, A | 1 |
| Makrygiannis, SS | 1 |
| Velissaris, D | 1 |
| Batika, PC | 1 |
| Argyrakis, KS | 1 |
| Tzerefos, SP | 1 |
| Prekates, AA | 1 |
| Foussas, SG | 1 |
| Hsu, CP | 1 |
| Lin, SJ | 1 |
| Chung, MY | 1 |
| Lu, TM | 1 |
| Gallina, S | 1 |
| Patruno, A | 1 |
| Ohnishi, M | 1 |
| Wada, A | 1 |
| Tsutamoto, T | 1 |
| Fujii, M | 1 |
| Matsumoto, T | 1 |
| Yamamoto, T | 1 |
| Takayama, T | 1 |
| Kinoshita, M | 1 |
| Zoccali, C | 2 |
| Kielstein, JT | 1 |
| Klein, G | 1 |
| Graf, S | 1 |
| Haller, H | 1 |
| Fliser, D | 1 |
| Saitoh, M | 1 |
| Osanai, T | 1 |
| Kamada, T | 1 |
| Matsunaga, T | 1 |
| Ishizaka, H | 1 |
| Hanada, H | 1 |
| Okumura, K | 1 |
| Niebauer, J | 1 |
| Clark, AL | 1 |
| Webb-Peploe, KM | 1 |
| Böger, R | 1 |
| Coats, AJ | 1 |
| Mallamaci, F | 1 |
| Tripepi, G | 1 |
| Cutrupi, S | 1 |
| Malatino, LS | 1 |
| Eichinger, J | 1 |
| Young, JM | 1 |
| Strey, CH | 1 |
| George, PM | 1 |
| Florkowski, CM | 1 |
| Sies, CW | 1 |
| Frampton, CM | 1 |
| Scott, RS | 1 |
| Usui, M | 1 |
| Matsuoka, H | 1 |
| Miyazaki, H | 1 |
| Ueda, S | 1 |
| Okuda, S | 1 |
| Imaizumi, T | 1 |
| Feng, Q | 1 |
| Lu, X | 1 |
| Fortin, AJ | 1 |
| Pettersson, A | 1 |
| Hedner, T | 1 |
| Kline, RL | 1 |
| Arnold, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease[NCT05719714] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| EXerCise Introduction To Enhance Performance in Dialysis: the EXCITE Study[NCT01255969] | Phase 4 | 500 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for n(g),n(g')-dimethyl-l-arginine and Heart Failure
| Article | Year |
|---|---|
Prognostic Value of Asymmetric Dimethylarginine in Patients with Heart Failure: A Systematic Review and Meta-analysis.
Topics: Aged; Arginine; Heart Failure; Humans; Middle Aged; Prognosis | 2020 |
Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease.
Topics: Amidohydrolases; Animals; Arginine; Endothelium, Vascular; Heart Failure; Humans; Nitric Oxide Synth | 2018 |
Asymmetric dimethylarginine and critical illness.
Topics: Amidohydrolases; Arginine; Critical Illness; Enzyme Inhibitors; Heart Failure; Humans; Intensive Car | 2014 |
Nutritional factors in the prevention and management of coronary artery disease and heart failure.
Topics: Alprostadil; Anti-Inflammatory Agents; Arginine; CD59 Antigens; Coronary Artery Disease; Diabetes Me | 2015 |
Effect of asymmetric dimethylarginine (ADMA) on heart failure development.
Topics: Amidohydrolases; Animals; Arginine; Heart Failure; Humans; Nitric Oxide; Nitric Oxide Synthase; omeg | 2016 |
9 trials available for n(g),n(g')-dimethyl-l-arginine and Heart Failure
| Article | Year |
|---|---|
The impact of probiotic yogurt versus ordinary yogurt on serum sTWEAK, sCD163, ADMA, LCAT and BUN in patients with chronic heart failure: a randomized, triple-blind, controlled trial.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Arginine; Blood Urea Nitrogen; Cytokine TWE | 2022 |
Relationship between exercise intervention and NO pathway in patients with heart failure with preserved ejection fraction.
Topics: Aged; Arginine; Biomarkers; Exercise Therapy; Female; Follow-Up Studies; Heart Failure; Humans; Male | 2018 |
Chronic heart failure and aging - effects of exercise training on endothelial function and mechanisms of endothelial regeneration: Results from the Leipzig Exercise Intervention in Chronic heart failure and Aging (LEICA) study.
Topics: Aged; Aging; Arginine; Blood Flow Velocity; Cell Count; Chemokine CXCL12; Endothelial Progenitor Cel | 2016 |
Acute effects of 5-methyltetrahydrofolate on endothelial function and asymmetric dimethylarginine in patients with chronic heart failure.
Topics: Aged; Arginine; Chronic Disease; Endothelium, Vascular; Female; Heart Failure; Hemodynamics; Humans; | 2010 |
Effects of walking on heart rate recovery, endothelium modulators and quality of life in patients with heart failure.
Topics: Aged; Analysis of Variance; Arginine; Biomarkers; Chronic Disease; Endothelium, Vascular; Exercise T | 2011 |
The biological evaluation of ADMA/SDMA and eNOS in patients with ACHF.
Topics: Adult; Aged; Alanine Transaminase; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2013 |
Home-based exercise training modulates pro-oxidant substrates in patients with chronic heart failure.
Topics: Adult; Arginine; Cross-Over Studies; Exercise; Female; Heart Failure; Humans; Hypoxanthine; Male; Mi | 2005 |
Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with non-ischaemic heart failure.
Topics: Arginine; Atorvastatin; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Heart Failur | 2008 |
Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure.
Topics: Arginine; Echocardiography; Enzyme Inhibitors; Female; Heart Failure; Humans; Male; Middle Aged; Nit | 1998 |
27 other studies available for n(g),n(g')-dimethyl-l-arginine and Heart Failure
| Article | Year |
|---|---|
Association of urine and plasma ADMA with atherosclerotic risk in DKD cardiovascular disease risk in diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study.
Topics: Arginine; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus; D | 2023 |
Serum concentrations of asymmetric and symmetric dimethylarginine are associated with mortality in acute heart failure patients.
Topics: Acute Disease; Aged; Aged, 80 and over; Arginine; Biomarkers; Cohort Studies; Female; Heart Failure; | 2018 |
Alterations in plasma L-arginine and methylarginines in heart failure and after heart transplantation.
Topics: Arginine; Biomarkers; Citrulline; Endothelium, Vascular; Female; Heart Failure; Heart Transplantatio | 2018 |
Effects of eicosapentaenoic acid on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure patients with dyslipidemia.
Topics: Aged; Arginine; Biomarkers; Chemokine CCL2; Chromatography, High Pressure Liquid; Chronic Disease; D | 2014 |
Cardioprotective effects of oxymatrine on isoproterenol-induced heart failure via regulation of DDAH/ADMA metabolism pathway in rats.
Topics: Alkaloids; Amidohydrolases; Animals; Arginine; Cardiotonic Agents; Disease Models, Animal; Female; H | 2014 |
Nitric oxide dysregulation in patients with heart failure: the association of depressive symptoms with L-arginine, asymmetric dimethylarginine, symmetric dimethylarginine, and isoprostane.
Topics: Aged; Arginine; Depression; Female; Heart Failure; Humans; Isoprostanes; Linear Models; Male; Middle | 2015 |
Higher serum asymmetric dimethylarginine is related to higher risk of heart failure in the EPIC-Potsdam study.
Topics: Adult; Aged; Arginine; Biomarkers; Feeding Behavior; Female; Germany; Heart Failure; Humans; Male; M | 2017 |
Plasma asymmetric dimethylarginine and cardiovascular events in patients with acute decompensated heart failure.
Topics: Aged; Arginine; Austria; Cohort Studies; Female; Heart Failure; Humans; Male; Middle Aged; Natriuret | 2008 |
Differential long-term effects of carvedilol on proinflammatory and antiinflammatory cytokines, asymmetric dimethylarginine, and left ventricular function in patients with heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Arginine; Carbazoles; Carvedilol; C | 2008 |
Smoker's paradox in heart failure: might asymmetric dimethylarginine be the possible explanation?
Topics: Arginine; Cardiovascular Diseases; Heart Failure; Hospital Mortality; Humans; Smoking | 2008 |
Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production.
Topics: Adenoviridae; Animals; Arginine; Atherosclerosis; Chlorocebus aethiops; Citrulline; COS Cells; Diabe | 2010 |
Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart: a key role for ubiquitin-conjugating enzymes.
Topics: Animals; Arginine; Down-Regulation; Endothelial Cells; Endothelium, Vascular; Heart Failure; Humans; | 2011 |
The L-arginine-asymmetric dimethylarginine ratio is strongly related to the severity of chronic heart failure. No effects of exercise training.
Topics: Aged; Aged, 80 and over; Arginine; Endothelium, Vascular; Exercise Therapy; Exercise Tolerance; Fema | 2011 |
Inflammation and reduced endothelial function in the course of severe acute heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Arginine; Biomarkers; Case-Control Studies; Endothelium, Vas | 2011 |
The effect of pharmacological treatment on ADMA in patients with heart failure.
Topics: Aged; Arginine; Female; Heart Failure; Humans; Male; Middle Aged | 2011 |
The biological effect of pharmacological treatment on dimethylaminohydrolases (DDAH-1) and cationic amino acid transporter-1 (CAT-1) expression in patients with acute congestive heart failure.
Topics: Acute Disease; Aged; Amidohydrolases; Arginine; Cardiovascular Agents; Cationic Amino Acid Transport | 2011 |
Endothelial dysfunction of the peripheral vascular bed in the acute phase after ischemic stroke.
Topics: Aged; Analysis of Variance; Arginine; Biomarkers; Blood Pressure; Case-Control Studies; Endothelium, | 2012 |
Plasma asymmetric dimethylarginine and mortality in patients with acute decompensation of chronic heart failure.
Topics: Aged; Arginine; Biomarkers; Endothelium, Vascular; Enzyme Inhibitors; Female; Follow-Up Studies; Gre | 2012 |
Plasma asymmetric dimethylarginine in patients with acute decompensation of chronic heart failure.
Topics: Arginine; Enzyme Inhibitors; Female; Heart Failure; Humans; Male | 2012 |
Asymmetric dimethylarginine predicts clinical outcomes in ischemic chronic heart failure.
Topics: Aged; Aged, 80 and over; Arginine; Biomarkers; Chi-Square Distribution; Chromatography, High Pressur | 2012 |
Endothelin stimulates an endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine, in experimental heart failure.
Topics: Animals; Arginine; Cardiac Output; Cardiac Pacing, Artificial; Dogs; Endothelin Receptor Antagonists | 2002 |
ADMA: a critical cardio-renal link in heart failure?
Topics: Arginine; Heart Failure; Humans; Kidney Failure, Chronic; Nitric Oxide | 2003 |
Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure.
Topics: Aged; Arginine; Endothelium, Vascular; Heart Failure; Humans; Kidney Diseases; Male; Renal Circulati | 2003 |
High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level.
Topics: Acute Disease; Arginine; Chromatography, High Pressure Liquid; Chronic Disease; Cytokines; Enzyme In | 2003 |
Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD.
Topics: Adult; Aged; Arginine; Arteriosclerosis; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; En | 2005 |
Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure.
Topics: Aged; Arginine; Austria; Biomarkers; Disease-Free Survival; Female; Heart Failure; Humans; Male; Nat | 2007 |
Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Arginine; Endothelium, Vascular; Heart Failure; Kidney; Mal | 1998 |